IBRUTINIB PLUS PALBOCICLIB HAS EFFICACY IN MANTLE CELL LYMPHOMA

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2019年 / 9卷 / 03期
关键词：
D O I：
10.1158/2159-8290.CD-RW2019-016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The BTK inhibitor ibrutinib plus the CDK4 inhibitor palbociclib achieves responses in 67% of MCL patients. © 2019 American Association for Cancer Research.
引用
收藏
页码：318 / 318
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of ibrutinib in mantle cell lymphoma: A systematic review and meta-analysis
    Roufarshbaf, Mohammad
    Javeri, Mohsen
    Akbari, Vajihe
    Matin, Payman Hosseini
    Farrokhi, Pegah
    Sadeghi, Erfan
    Heidari, Zahra
    Moghaddas, Azadeh
    DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 30 (02) : 367 - 378
  • [22] Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib
    Sun, Kai
    Kasparian, Saro
    Iyer, Swaminathan
    Pingali, Sai Ravi
    ECANCERMEDICALSCIENCE, 2018, 12
  • [23] Overcoming Mantle Cell Lymphoma's Ibrutinib Resistance
    Sinha, Gunjan
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (11):
  • [24] Can we improve on ibrutinib in mantle cell lymphoma?
    Rule, Simon
    LANCET HAEMATOLOGY, 2018, 5 (03): : E98 - E99
  • [25] Ibrutinib-associated Serositis in Mantle Cell Lymphoma
    Styskel, Brett A.
    Lopez-Mattei, Juan
    Jimenez, Carlos A.
    Stewart, John
    Hagemeister, Fredrick B.
    Faiz, Saadia A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199 (12) : E43 - E44
  • [26] Overcoming primary ibrutinib resistance in mantle cell lymphoma
    Zhang, Leo
    Lan Pham
    Zhang, Hui
    Xie, Jingmeng
    Tao, Wenjing
    Bell, Taylor
    Chen, Zhihong
    Nomie, Krystle
    Fang, Bingliang
    Wang, Michael
    CANCER RESEARCH, 2016, 76
  • [27] Molecular Profiling plus In Vitro and In Vivo Drug Efficacy Analyses Identifies Novel Treatments to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma
    Liu, Yang
    Nomie, Krystle
    Jiang, Changying
    Yao, Yixin
    Zhang, Liang
    Wang, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S318 - S318
  • [28] The efficacy of ibrutinib-based combination therapy for mantle cell lymphoma: A systematic review.
    Thirunagari, Prem
    Siyahian, Aida
    Iftikhar, Ahmad
    Wahab, Ahsan
    Ashraf, Afia
    Majeed, Ammara
    Parr, Nadia C. Nunes Cavalcante
    Russ, Atlantis Dawn
    Kumar, Abhijeet
    Anwer, Faiz
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
    Izutsu, Koji
    Goto, Hideki
    Kizaki, Masahiro
    Yamaguchi, Masaki
    Fukuhara, Noriko
    Kato, Koji
    Saito, Toko
    Terui, Yasuhito
    Okubo, Sumiko
    Soshin, Tomomi
    Mukherjee, Nabanita
    Honda, Hideyuki
    Badawi, Mohamed
    Ross, Jeremy
    Ishizawa, Kenichi
    ANNALS OF ONCOLOGY, 2023, 34 : S1428 - S1428
  • [30] Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
    Goto, Hideki
    Ito, Satoshi
    Kizaki, Masahiro
    Yamaguchi, Masaki
    Fukuhara, Noriko
    Kato, Koji
    Saito, Toko
    Terui, Yasuhito
    Okubo, Sumiko
    Soshin, Tomomi
    Zeng, Jiewei
    Honda, Hideyuki
    Badawi, Mohamed
    Ross, Jeremy A.
    Izutsu, Koji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (02) : 232 - 240
12345